Freedom of Information

Title
Prescribing urothelial and colorectal cancer
Reference Number
RF23-434
Request Details
  1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?

• Avelumab
• Atezolizumab
• Carboplatin with Gemcitabine
• Carboplatin single or in any other combination
• Cisplatin with Gemcitabine
• Cisplatin single or in any other combination
• Nivolumab
• Pembrolizumab
• Any other systemic anti-cancer therapy
• Palliative care only

  1. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

  2. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?

• Aflibercept
• Bevacizumab
• Capecitabine
• CAPIRI
• CAPOX (XELOX)
• Cetuximab in combination with FOLFIRI/FOLFOX
• Cetuximab not in combination with FOLFIRI or FOLFOX
• Irinotecan only
• FOLFIRI
• FOLFOX
• Fluorouracil (5FU) only
• Oxaliplatin only
• Nivolumab
• Panitumumab in combination with FOLFIRI/FOLFOX
• Panitumumab not in combination with FOLFIRI or FOLFOX
• Pembrolizumab
• Raltitrexed
• Ramucirumab
• Regorafenib
• Tegafur + Uracil
• Any other systemic anti-cancer therapy
• Palliative care only

Response
  • rf23-434-response.pdf
    • Date of Disclosure
    15/08/2023